Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Rupa Narayan"'
Autor:
Rupa Narayan, Ana Alfonso Piérola, William B. Donnellan, Antonieta Molero Yordi, Maher Abdul‐Hay, Uwe Platzbecker, Marion Subklewe, Tapan Mahendra Kadia, Juan Manuel Alonso‐Domínguez, James McCloskey, Kathryn Bradford, Martin Curtis, Nikki Daskalakis, Christina Guttke, Karim Safer, Brett Hiebert, Joseph Murphy, Xiang Li, Ken Duchin, Daniel Esteban
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 3, Pp n/a-n/a (2024)
Abstract Relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) outcomes remain poor. A targeted cluster of differentiation (CD)33 × CD3 bispecific antibody, JNJ‐67571244, was assessed to identify the maximum tol
Externí odkaz:
https://doaj.org/article/274473cdc5184c6596ff63a5c9aab2bf
Autor:
Maher Abdul-Hay, Courtney Dinardo, Onyee Chan, Rupa Narayan, Ghayas Issa, Jennifer Michaelson, Patrick Baeuerle, Kristan Meetze, John Janik, Irina Shapiro, Judy Inumerable, Jeffery Jones, David Sallman
Publikováno v:
HemaSphere, Vol 7, p e6508781 (2023)
Externí odkaz:
https://doaj.org/article/793356c2ada740269d6fba876eef50b0
Autor:
Joan How, Siyang Ren, Jennifer Lombardi‐Story, Meghan Bergeron, Julia Foster, Phillip C. Amrein, Andrew M. Brunner, Amir T. Fathi, Hanno Hock, Anna Khachatryan, Hiroto Kikuchi, Mei Rosa Ng, Jenna Moran, Rupa Narayan, Donna Neuberg, Aura Ramos, Tina Som, Meghan Vartanian, Yi‐Bin Chen, Dan G. Duda, Gabriela S. Hobbs
Publikováno v:
eJHaem, Vol 3, Iss 2, Pp 434-442 (2022)
Abstract We conducted a single‐center, open‐label, dose escalation, and expansion phase I trial of the antiangiogenic multikinase inhibitor regorafenib in patients with advanced myeloid neoplasms. We enrolled 16 patients with relapsed/refractory
Externí odkaz:
https://doaj.org/article/b768134a01424428b03dc52b7afb2c56
Autor:
Valentina Nardi, Nora Ku, Matthew J. Frigault, Adrian M. Dubuc, Harrison Kwei Tsai, Philip C. Amrein, Gabriela S. Hobbs, Andrew M. Brunner, Rupa Narayan, Meghan E. Burke, Julia Foster, Paola Dal Cin, Marcela V. Maus, Amir T. Fathi, Hanno Hock
Publikováno v:
Blood Advances, Vol 4, Iss 1, Pp 106-111 (2020)
Abstract: Philadelphia chromosome (Ph)–like acute lymphoblastic leukemia (ALL) is a subtype of Ph-negative ALL that molecularly resembles Ph-positive ALL. It shares the adverse prognosis of Ph-positive ALL, but lacks the BCR-ABL1 fusion oncogene. I
Externí odkaz:
https://doaj.org/article/7fc7238856444e36b2853dd5b133bf4f
Autor:
Ashley Ott, Vinayak Venkataraman, Yousef R. Badran, Rose Goldman, Smiljana Spasic, Darshali A. Vyas, Philip Amrein, Steven McAfee, Andrew Brunner, Amir T. Fathi, Rupa Narayan
Publikováno v:
Clinical Case Reports, Vol 9, Iss 5, Pp n/a-n/a (2021)
Abstract Arsenic trioxide (ATO) is generally well tolerated for treatment of APL. We present a patient with severe watery diarrhea and pancreatitis thought to be due to ATO toxicity in the setting of obesity and acute kidney injury. Future studies ev
Externí odkaz:
https://doaj.org/article/494d082f35284bb09e1061365acbe062
Autor:
Rupa Narayan, Niclas Olsson, Lisa E Wagar, Bruno C Medeiros, Everett Meyer, Debra Czerwinski, Michael S Khodadoust, Lichao Zhang, Liora Schultz, Mark M Davis, Joshua E Elias, Ron Levy
Publikováno v:
PLoS ONE, Vol 14, Iss 7, p e0219547 (2019)
Somatic mutations in cancer are a potential source of cancer specific neoantigens. Acute myeloid leukemia (AML) has common recurrent mutations shared between patients in addition to private mutations specific to individuals. We hypothesized that neoa
Externí odkaz:
https://doaj.org/article/edb0390b578b4750b2577bb7b8e15027
Autor:
Amir T. Fathi, Geoffrey G Fell, Areej El-Jawahri, Alexander E. Perl, Brian A. Jonas, Ajoy L. Dias, Alice S. Mims, Uma Borate, Brittany Knick Ragon, Michael R. Grunwald, Mary Linton B. Peters, Timothy A. Graubert, Philip C. Amrein, Hanno R. Hock, Andrew M. Brunner, Gabriela S. Hobbs, Rupa Narayan, Donna S. Neuberg, Ibrahim Aldoss
Publikováno v:
Blood. 140:3284-3286
Autor:
Rupa Narayan, Abhishek Niroula, Tao Wang, Michelle Kuxhausen, Meilun He, Everett Meyer, Yi-Bin Chen, Vijaya Raj Bhatt, Amer Beitinjaneh, Taiga Nishihori, Akshay Sharma, Valerie I. Brown, Malek Kamoun, Miguel A. Diaz, Muhammad Bilal Abid, Medhat Askar, Christopher G. Kanakry, Loren Gragert, Yung-Tsi Bolon, Steven G.E. Marsh, Shahinaz M. Gadalla, Sophie Paczesny, Stephen Spellman, Stephanie J. Lee
Publikováno v:
Transplantation and Cellular Therapy.
Autor:
Valentina Nardi, Steven L McAfee, Paola Dal Cin, Harrison K Tsai, Philip C Amrein, Gabriela S Hobbs, Andrew M Brunner, Rupa Narayan, Julia Foster, Amir T Fathi, Hanno Hock
Publikováno v:
The Oncologist. 27:82-86
BCR-ABL1 kinase inhibitors have improved the prognosis of Philadelphia-chromosome-positive (Ph+)-acute lymphoblastic leukemia (ALL). Ph-like (or BCR-ABL1-like) ALL does not express BCR-ABL1 but commonly harbors other genomic alterations of signaling
Autor:
Amir T. Fathi, Haesook T. Kim, Robert J. Soiffer, Mark J. Levis, Shuli Li, Annette S. Kim, Alice S. Mims, Zachariah DeFilipp, Areej El-Jawahri, Steven L. McAfee, Andrew M. Brunner, Rupa Narayan, Laura W. Knight, Devon Kelley, AJ S. Bottoms, Lindsey H. Perry, Jonathan L. Wahl, Jennifer Brock, Elayne Breton, Vincent T. Ho, Yi-Bin Chen
Publikováno v:
Blood advances. 6(22)
IDH2 (isocitrate dehydrogenase 2) mutations occur in approximately 15% of patients with acute myeloid leukemia (AML). The IDH2 inhibitor enasidenib was recently approved for IDH2-mutated relapsed or refractory AML. We conducted a multi-center, phase